Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies

Bispecific antibodies (bsAb) and chimeric antigen receptor (CAR) T cells allow for antibody guided recruitment of T cells against tumors. Both are successfully used for treatment of CD19 expressing leukemias, but may cause cytokine release syndrome (CRS) as a major dose-limiting side effect. For CRS...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauer, Joseph, Hörner, Sebastian, Osburg, Lukas, Müller, Stefanie, Märklin, Melanie, Heitmann, Jonas S, Zekri, Latifa, Rammensee, Hans-Georg, Salih, Helmut R, Jung, Gundram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264835/
https://www.ncbi.nlm.nih.gov/pubmed/32474413
http://dx.doi.org/10.1136/jitc-2020-000621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264835/
https://www.ncbi.nlm.nih.gov/pubmed/32474413
http://dx.doi.org/10.1136/jitc-2020-000621

Ejemplares similares